Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Peregrine Investors: Once Bitten, Twice Shy

This morning, Peregrine Pharmaceuticals (NASDAQ: PPHM  ) released additional details regarding its revised analysis of bavituximab in non-small cell lung cancer. Today's release comes less than a week after investors totally misinterpreted clinical data on the drug used in pancreatic cancer, initially bidding up shares before a sharp sell-off later in the day. As Brenton Flynn outlines in the video below, this time around the investor reaction has been much more rational.

The ying to Peregrine's yang?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand new premium report on Celgene. To claim your copy today -- along with a free year of updates -- simply click here now.

Read/Post Comments (3) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 19, 2013, at 12:31 PM, BSDetector wrote:

    I had hope for you guys after your last video on PPHM. I was convinced that you were FINALLY starting to get it. Not so.

    You appear to have no clue how hedge funds & big pharma operates in light of today's news.

    For the record; it should have opened at $4+ today. Manipulation can be a bit of a biotch however when hedge funds missed the boat & BP needs to keep the price in check.

    Obviously you won't get it until partnership is announced in the next few weeks and the stock explodes like Spindletop.

    Owner since 0.80

  • Report this Comment On February 19, 2013, at 3:59 PM, BSDetector wrote:

    Once Written, Twice Shy(ster)

    It has come to my attention that you merely fill in for Adam Fraudstain of The Street when hedge funds find it impossible to put a negative spin on recent news.

    I apologize to myself for wasting my time in trying to educate you. Best of luck in Adam's school of bashing. I hear The Street offers excellent benefits as well as an idiot protection program when they are ready to discard you.

  • Report this Comment On February 19, 2013, at 4:18 PM, foome1x wrote:


Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2262939, ~/Articles/ArticleHandler.aspx, 9/24/2016 11:57:45 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
PPHM $0.41 Down -0.01 -2.31%
Peregrine Pharmace… CAPS Rating: **
CELG $109.43 Down -1.14 -1.03%
Celgene CAPS Rating: *****